MRM1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: HEPG2 and K562 cell lysates, Primary antibody: P02832(MRM1 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02832(MRM1 Antibody) at dilution 1/85. (Original magnification: ×200)    

  
  

The MRM1 antibody is primarily associated with research on mitochondrial RNA modifications and related cellular processes. MRM1 (Mitochondrial rRNA Methyltransferase 1), also known as FTSJ2. is an enzyme responsible for catalyzing the 2'-O-methylation of ribosomal RNA (rRNA) in mitochondria, a critical post-transcriptional modification ensuring proper mitochondrial ribosome assembly and translational fidelity. Dysregulation of MRM1 has been linked to mitochondrial dysfunction, which is implicated in metabolic disorders, neurodegenerative diseases, and aging.

Antibodies targeting MRM1 are used to study its expression, localization, and interaction partners in cellular models. They enable detection via techniques like Western blotting, immunofluorescence, or immunoprecipitation, aiding investigations into mitochondrial gene expression mechanisms. Research using MRM1 antibodies has revealed its role in maintaining mitochondrial respiratory chain activity and its potential as a biomarker for mitochondrial diseases. However, commercial availability of MRM1-specific antibodies remains limited, and validation across species or experimental conditions requires careful optimization. Current studies focus on elucidating how MRM1-mediated rRNA modifications influence metabolic reprogramming in cancer or age-related pathologies, highlighting its therapeutic relevance.